In:
Journal of Obstetrics and Gynaecology Research, Wiley, Vol. 40, No. 3 ( 2014-03), p. 806-811
Abstract:
To determine the survival and prognostic factors of patients with primary fallopian tube cancer ( PFTC ) who had been treated with paclitaxel and carboplatin chemotherapy. Methods The records of patients with PFTC who had been treated between 2002 and 2010, identified through the report of C hiang M ai U niversity H ospital, were reviewed. All patients had pathological materials initially reported or reviewed by a gynecologic pathologist before initiation of treatment. Results Thirty patients met the inclusion criteria. Median age was 51 years. Serous adenocarcinoma was observed in the majority of patients (76.7%). Approximately 46% of patients were in stage I – II . The 5‐year progression‐free survival ( PFS ) for all patients was 37.2%. The 5‐year PFS was 75.0% for stage I , 51.4% for stage II and 18.5% for stage III . Median PFS of the entire cohort was 26.0 months with a 95% confidence interval ( CI ) of 18.7–33.3 months. This rate was 18.5 months (95% CI , 6.7–35.6) for stage III whereas it was not reached for patients of stage I – II . Serous histology and stage were noted to be significant independent predictors of PFS with an adjusted hazards ratio of 7.54 (95% CI , 1.34–42.4) and 6.19 (95% CI , 1.59–24.08), respectively. Conclusion The 5‐year PFS of the whole cohort was 37.2% with a median survival of 26 months. I nternational F ederation of G ynecology and O bstetrics stage and histological subtype were a significant independent factor for predicting PFS .
Type of Medium:
Online Resource
ISSN:
1341-8076
,
1447-0756
DOI:
10.1111/jog.2014.40.issue-3
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2079101-X